Genflow Biosciences will present full results from its canine ageing trial at the Animal Longevity Summit in Toronto, highlighting the safety and potential health benefits of its GF-1004 treatment aimed at slowing ageing. The company is also progressing a glaucoma program using lipid nanoparticle technology and seeking funding to extend its liver disease research. With improved financials and ongoing talks with animal health partners, Genflow views its veterinary work as a commercial and research platform for human therapies. However, it notes the need for further funding and uncertainty about its continued operations.
Genflow Biosciences' canine ageing trial results come as Pluang reports on the health sector market. For readers following health stocks, here is Pluang's market snapshot as of Sep 29, 2026 14:01 WIB: out of 100 priced US health-sector stocks, 38 rose and 51 fell today. Notable movers include Adaptive Biotechnologies Corp (ADPT) at USD 28.40 with a 1-day change of -3.50% and 100% buy order activity, Teladoc Health Inc (TDOC) at USD 5.88 down 3.45%, and Abeona Therapeutics Inc (ABEO) at USD 5.13 down 3.02%.
The cryptocurrency AAVE surged 9.31% within four hours to reach $163, extending its 24-hour gain to 10.07%. This price increase was accompanied by $140,000 in short liquidations on major exchanges like Binance, Bybit, and OKX, while no long liquidati...
On September 28, all four major crypto spot ETFs—Bitcoin, Ethereum, Solana, and XRP—recorded net inflows totaling about $65 million, highlighting growing institutional demand beyond Bitcoin alone. Bitcoin ETFs led with $31.07 million, followed by Eth...
Poolbeg Pharma has secured funding to complete its clinical trials through to the second quarter of 2028. The company is currently recruiting patients for its TOPICAL trial of POLB 001, a drug aimed at preventing cytokine release syndrome in cancer p...
Bitcoin's price fell below $83,000 on September 28-29, triggering the liquidation of about $500 million in leveraged crypto positions and impacting 129,197 traders. The drop was influenced by rising oil prices after geopolitical tensions and a rare 3...
Telo Genomics announced new clinical research showing its blood-based TELO-MRD test detects residual multiple myeloma cells more sensitively than traditional bone marrow tests like Adaptive clonoSEQ. The TELO-MRD liquid biopsy identifies circulating ...
